United States · Platforms & data · MarketBeat
What MediWound (MDWD) Said on Its Q3 Earnings Call
Detailed summary
MediWound (NASDAQ:MDWD) reported lower third-quarter revenue and a wider net loss as it increased spending on its late-stage EscharEx trial, while executives said manufacturing constraints continue to limit sales of its burn treatment NexoBrid. The company expects to complete enrollment and an inte
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)
